Bristol Entecavir Goes To Antiviral Advisory Committee March 11
This article was originally published in The Pink Sheet Daily
Executive Summary
The oral nucleoside analogue is pending at FDA for treatment of chronic hepatitis B infection and is receiving a priority review. Bristol's Phase III trials show statistically significant improvements compared to GlaxoSmithKline's Epivir-HBV.